Search results
Results from the WOW.Com Content Network
Lacosamide, sold under the brand name Vimpat among others, is a medication used for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures. [2] It is used by mouth or intravenously .
The drug or other substance has a high potential for abuse. The drug or other substance has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use of the drug or other substance under medical supervision. Examples: heroin, LSD, marijuana, MDMA (ecstasy), methaqualone (quaalude). Schedule II
The drug or other substance has a high potential for abuse. The drug or other substance has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use of the drug or other substance under medical supervision. The complete list of Schedule I substances is as follows. [1]
Treatment Improvement Protocols (TIPs) are a series of best-practice manuals for the treatment of substance use and other related disorders. The TIP series is published by the Substance Abuse and Mental Health Services Administration (SAMHSA), an operational division of the U.S. Department of Health and Human Services .
Controlled Substances; Long title: An Act to amend the Public Health Service Act and other laws to provide increased research into, and prevention of, drug abuse and drug dependence; to provide for treatment and rehabilitation of drug abusers and drug dependent persons; and to strengthen existing law enforcement authority in the field of drug abuse.
Julius Wagner-Jauregg's discovery in 1917 of malaria-induced fever therapy for neurosyphilis highlighted the potential of physical methods to treat mental diseases. [3] This innovative approach, leveraging the therapeutic effects of severe fever, drew inspiration from ancient observations and scientific insights dating back to Hippocrates. [3]
The Drug Addiction Treatment Act of 2000 (DATA 2000), Title XXXV, Section 3502 of the Children's Health Act, permits physicians who meet certain qualifications to treat opioid addiction with Schedule III, IV, and V narcotic medications that have been specifically approved by the Food and Drug Administration for that indication.
In December 2021, the National Medical Products Administration reclassified all oral single-component dextromethorphan to prescription drugs due to potential abuse. The authorities also mandated manufacturers to remove statements like "no addiction or tolerance with long-term use" from their instructions. [ 38 ]